Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study
ERA demonstrated a better steroid-sparing effect and a possibility of earlier remission or low disease activity, except for lupus nephritis. Further investigations are required.
Authors
- Rinat K. Raupov (ORCID: https://orcid.org/0000-0001-7749-6663)
- Natalia Lubimova
- I. Z. Gaydukova (ORCID: https://orcid.org/0000-0003-3500-7256)
- Olga Kalashnikova (ORCID: https://orcid.org/0000-0002-8683-4270)
- Lyubov Sorokina
- E. Gaidar (ORCID: https://orcid.org/0000-0002-0971-2018)
- E.A. Isupova (ORCID: https://orcid.org/0000-0002-0911-7817)
- D. B. Aliev (ORCID: https://orcid.org/0000-0001-8367-4622)
- И. А. Чикова (ORCID: https://orcid.org/0000-0003-4636-5825)
- Mikhail Mikhaylovich Kostik (ORCID: https://orcid.org/0000-0002-1180-8086)
- Maria Kaneva (ORCID: https://orcid.org/0000-0002-9540-2592)
- Elvira Kalashnikova
Institutions
- Federal Almazov North-West Medical Research Centre (RU)
- North-Western State Medical University named after I.I. Mechnikov (RU)
- The Turner Scientific Research Institute for Children's Orthopedics (RU)
- Center for Rheumatology (US)
- Yandex (Russia) (RU)
- Saint Petersburg State Pediatric Medical University (RU)
Publication Details
- Journal
- World Journal of Nephrology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.5527/wjn.v13.i4.98393
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Russian Science Foundation
- Ministry of Science and Higher Education of the Russian Federation